NUDT15中间代谢型与接受英夫利西单抗联合硫唑嘌呤治疗的儿童克罗恩病患者较低的应答丢失相关
这项回顾性观察研究纳入143例接受英夫利西单抗(IFX)联合硫唑嘌呤(AZA)治疗的儿童克罗恩病(CD)患者,比较NUDT15正常代谢型与中间代谢型组的结局。中间代谢型组应答丢失(LOR)显著更低(6.5% vs 27.7%,P=0.025),IFX持续使用率显著更高(96.8% vs 80.4%,P=0.027),1年临床缓解、生化缓解、黏膜愈合及IFX谷浓度、抗IFX抗体、6-硫鸟嘌呤核苷酸水平两组无显著差异。
要点
- NUDT15中间代谢型组LOR为6.5%,正常代谢型组为27.7%,差异有统计学意义(P=0.025)。
- NUDT15中间代谢型组IFX持续使用率为96.8%,正常代谢型组为80.4%(P=0.027)。
- 多变量Cox回归显示抗IFX抗体阳性与LOR相关(HR 4.76,95%CI 2.25-10.07,P<0.001)。
核心结论
- NUDT15中间代谢型与接受IFX联合AZA治疗的儿童CD患者较低的LOR相关。
- 该发现可能部分解释韩国儿童中IFX持续使用时间长于西方国家儿童的现象。
研究设计与样本
- 回顾性观察研究,纳入143例接受英夫利西单抗(IFX)联合硫唑嘌呤(AZA)治疗的儿童克罗恩病(CD)患者,分为NUDT15正常代谢型组与中间代谢型组进行比较。
主要发现
- 1年临床缓解、生化缓解、黏膜愈合在两组间无显著差异,IFX谷浓度、抗IFX抗体及6-硫鸟嘌呤核苷酸水平两组相当。
- 中间代谢型组LOR为6.5%,正常代谢型组为27.7%,中间代谢型组显著更低(P=0.025)。
- 中间代谢型组IFX持续使用率为96.8%,正常代谢型组为80.4%,中间代谢型组显著更高(P=0.027)。
- 多变量Cox比例风险回归显示,抗IFX抗体阳性(HR 4.76,95%CI 2.25-10.07,P<0.001)及NUDT15代谢型分组与LOR相关(HR 0.18,95%CI 0.04-0.76,P=0.019)。
- Kaplan-Meier生存曲线显示正常代谢型组无LOR生存率显著更低(log-rank检验P=0.009)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: NUDT15 polymorphisms are associated with leukopenia during treatment with thiopurines. However, data regarding its effect on treatment outcomes are scarce. AIMS: To investigate the outcomes between NUDT15 normal and intermediate metabolisers in paediatric patients with Crohn's disease (CD) treated with a combination therapy of infliximab (IFX) and azathioprine (AZA). METHODS: In this retrospective observational study, 143 patients categorised into the NUDT15 normal and intermediate metaboliser groups were compared based on clinical remission (CR), biochemical remission (BR), mucosal healing (MH) at 1 year treatment, IFX trough levels (TLs), antibodies to IFX (ATIs), 6-thioguanine nucleotide (6-TGN) levels, loss of response (LOR) and IFX durability. RESULTS: No significant differences were observed between the groups in CR, BR, MH at 1 year, whereas IFX TLs and ATIs and 6-TGN levels were comparable. However, LOR (6.5% vs 27.7%, P = 0.025) was significantly lower and IFX durability significantly higher (96.8% vs 80.4% P = 0.027) in the intermediate group. Multivariable Cox proportional hazard regression analysis showed that ATI positivity (hazard ratio (HR): 4.76, 95% CI: 2.25-10.07, P < 0.001) and the NUDT15 metaboliser group was associated with LOR (HR: 0.18, 95% CI: 0.04-0.76, P = 0.019). The Kaplan-Meier survival curves showed that the LOR-free survival rate was significantly lower in normal metabolisers (log-rank test P = 0.009). CONCLUSION: NUDT15 intermediate metabolisers were associated with lower LOR in paediatric patients with CD treated with IFX and AZA combination therapy. This finding may partially explain the longer durability of IFX in Korean children than their counterparts in Western countries.
引用
- Kim ES, Choi S, Choi SY, et al. NUDT15 intermediate metabolisers are associated with lower loss of response in paediatric Crohn's disease patients treated by combination treatment with infliximab and azathioprine. Aliment Pharmacol Ther. 2022. PMID: 35032047. doi:10.1111/apt.16769
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。